< Clinical Trials

Ligelizumab Study

A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy

Study Eligibility

  1. Male or female participants who are ≥ 6 and ≤ 55 years of age at the time of signing informed consent/assent.  
  2. Documented medical history of allergy to peanuts or peanut-containing foods.
  3. Positive peanut-specific immunoglobulin E (peanut sIgE), ≥ 0.35 kUA/L at Screening Visit 1.Screening
  4. A positive peanut oral food challenge at baseline. (Eligibility to proceed with the food challenge requires fulfillment of all other eligibility criteria.)
  5. Participants must weigh ≥ 20 kg at Screening Visit 1.

Contact Information

Phone: 501-364-3886
Email: whitesided@archildrens.org